Doses of primaquine administered to children with Plasmodium vivax according to an age-based dose regimen

References

• World Health Organization. World malaria report 2019. Geneva: WHO; 2019.
   Google Scholar
• World Health Organization. Guidelines for the treatment of malaria. 3rd ed. Geneva: WHO; 2015.
   Google Scholar
• Fernando D, Rodrigo C, Rajapakse S. Primaquine in vivax malaria: an update and review on management issues. Malar J. 2011;10:351.
   Google Scholar
• Chu CS, White NJ. Management of relapsing Plasmodium vivax malaria. Expert Rev Anti Infect Ther. 2016;14:885–900.
   Google Scholar
• White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J. 2011;10:297.
   Google Scholar
• Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malar J. 2014;13:418.
   Google Scholar
• Taylor WRJ, Thriemer K, von Seidlein L, et al. Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet. 2019;394(10202):929–938.
   Google Scholar
• Krudsood S, Tangpukdee N, Wilairatana P, et al. High-dose primaquine regimens against relapse of Plasmodium vivax malaria. Am J Trop Med Hyg. 2008;78(5):736–740.
   Google Scholar
• Thomas D, Tazerouni H, Sundararaj KG, et al. Therapeutic failure of primaquine and need for new medicines in radical cure of Plasmodium vivax. Acta Trop. 2016;160:35–38.
   Google Scholar
• Collins WE, Jeffery GM. Primaquine resistance in Plasmodium vivax. Am J Trop Med Hyg. 1996;55(3):243–249.
   Google Scholar
• John GK, Douglas NM, von Seidlein L, et al. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J. 2012;11:280.
   Google Scholar
• Baird JK, Rieckmann KH. Can primaquine therapy for vivax malaria be improved? Trends Parasitol. 2003;19(3):115–120.
   Google Scholar
• Rishikesh K, Saravu K. Primaquine treatment and relapse in Plasmodium vivax malaria. Pathog Glob Health. 2016;110:1–8.
   Google Scholar
• Gonçalves BP, Pett H, Tiono AB, et al. Age, weight, and CYP2D6 genotype are major determinants of primaquine pharmacokinetics in African children. Antimicrob Agents Chemother. 2017;61:e02590–16.
   Google Scholar
• Poespoprodjo JR, Fobia W, Kenangalem E, et al. Vivax malaria: a major cause of morbidity in early infancy. Clin Infect Dis. 2009;48:1704–1712.
   Google Scholar
• BRASIL. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância Epidemiológica. Guia prático de tratamento da malária no Brasil. Brasília: Ministério da Saúde; 2010 [cited 2020 Apr 20]. Avaliable from: https://bvsms.saude.gov.br/bvs/publicacoes/guia_pratico_malaria.pdf
   Google Scholar
• Leang R, Khu NH, Mukaka M, et al. An optimised age-based dosing regimen for single low-dose primaquine for blocking malaria transmission in Cambodia. BMC Med. 2016;14(1):171.
   Google Scholar
• Simoes LR, Alves ER Jr, Ribatski-Silva D, et al. Factors associated with recurrent Plasmodium vivax malaria in Porto Velho, Rondônia State, Brazil, 2009. Cad Saude Publica. 2014;30:1403–1414.
   Google Scholar
• BRASIL. Ministério da Saúde. Secretaria de Vigilância em Saúde. Lista de municípios pertencentes às áreas de risco ou endêmicas para malária. [ cited 2020 Apr 18]. Available from: http://portalarquivos2.saude.gov.br/images/pdf/2019/junho/25/Lista-de-municipios-pertencentes-as-areas-de-risco-ou-endemicas-para-malaria.pdf
   Google Scholar
• Dua VK, Kar PK, Sarin R, et al. High-performance liquid chromatographic determination of primaquine and carboxyprimaquine concentrations in plasma and blood cells in Plasmodium vivax malaria cases following chronic dosage with primaquine. J Chromatogr B. 1996;675:93–98.
   Google Scholar
• Baird JK, Battle KE, Howes RE. Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms. Malar J. 2018;17:42.
   Google Scholar
• Durand S, Cabezas C, Lescano AG, et al. Efficacy of three different regimens of primaquine for the prevention of relapses of Plasmodium vivax malaria in the Amazon Basin of Peru. Am J Trop Med Hyg. 2014;9:18–26.
   Google Scholar
• Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157–1167.
   Google Scholar
• Chatelut E, Puisset F. The scientific basis of body surface area-based dosing. Clin Pharmacol Ther. 2014;95:359–361.
   Google Scholar
• Hayes DJ, Buuren SV, Ter Kuile FO, et al. Developing regional weight-for-age growth references for malaria endemic countries to optimize age-based dosing of antimalarials. Bull World Health Organ. 2015;93:74–83.
   Google Scholar
• Daher A, Silva JCAL, Stevens A, et al. Evaluation of Plasmodium vivax malaria recurrence in Brazil. Malar J. 2019;18(1):18.
   Google Scholar
• Mihaly GW, Ward SA, Edwards G, et al. Pharmacokinetics of primaquine in man- Identification of the carboxylic-acid derivative as a major plasma metabolite. Br J Clin Pharmacol. 1984;17:441–446.
   Google Scholar
• Bhatia SC, Saraph YS, Revankar SN, et al. Pharmacokinetics of primaquine in patients with Plasmodium vivax malaria. Eur J Clin Pharmacol. 1986;31:205–210.
   Google Scholar
• Fletcher KA, Price Evans DA, Gilles HM, et al. Studies on the pharmacokinetics of primaquine. Bull World Health Organ. 1981;59(3):407–412.
   Google Scholar
• Moore BR, Salman S, Benjamin J, et al. Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: feasibility of abbreviated high-dose regimens for radical cure of vivax malaria. Antimicrob Agents Chemother. 2014;58(1):432–439.
   Google Scholar